Cancer Therapy Via the Inhibition of Skp-2 Expression
OwnerHidetoshi Sumimoto, Yutaka Kawakami +2inventors
InventorsHidetoshi Sumimoto, Yutaka Kawakami, Makoto Miyagishi, Kazunari Taira
Life of this patent
Estimating the term…
Loading patent…
OwnerHidetoshi Sumimoto, Yutaka Kawakami +2inventors
InventorsHidetoshi Sumimoto, Yutaka Kawakami, Makoto Miyagishi, Kazunari Taira
Estimating the term…
The present invention is to provide: a double-stranded RNA (siRNA) capable of suppressing expression of Skp-2 gene, a double-stranded RNA expression cassette capable of expressing a double-stranded RNA, a double-stranded RNA expression vector containing a double-stranded RNA expression cassette, and highly safe therapeutic drug and therapy specific to cancers such as small cell lung cancer having Skp-2 as a molecular target. The RNAi target sequence is set in a plurality of sites in the protein translation region of Skp-2 mRNA, the expressed siRNA, which is a dsRNA exhibiting RNAi effect, is constructed on a lentiviral vector to construct a recombinant viral vector, and various small cell lung cancer cell lines and small cell lung cancers are infected with this viral vector, to confirm the cell proliferation suppression effect in vitro and the proliferation suppression effect in vivo.
A double-stranded RNA capable of suppressing expression of Skp-2 gene, which consists of a sense strand RNA and an antisense strand RNA homologous to a specific sequence of Skp-2 mRNA, which is a target of the double-stranded RNA.
Dependencies are inferred from the claim text.